No definition available.
Disorders of myoneural junction and muscle in diseases classified elsewhere
DOID EFO Endpoint Browser PheWeb
G6_MYOMUSCINOTH
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
290 |
4. Check minimum number of eventsNone |
290 |
5. Include endpointsNone |
290 |
6. Filter based on genotype QC (FinnGen only) |
279 |
Control definitions (FinnGen only)
- Control exclude
- G6_MYONEU
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Disorders of myoneural junction and muscle in diseases classified elsewhere
based on the number of shared cases.
Similar with more cases:
- Diseases of the myoneural junction and muscle
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
- Neurological diseases
- Neurological diseases, wide definition
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1357 | 973 | 377 |
| Only index persons | 1184 | 865 | 319 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.01 |
| Only index persons | 0.03 | 0.03 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 61.99 | 62.44 | 60.81 |
| Only index persons | 61.00 | 61.15 | 60.58 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 279 | 212 | 67 |
| Unadjusted period prevalence (%) | 0.06 | 0.08 | 0.03 |
| Median age at first event (years) | 57.33 | 56.43 | 60.16 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 290
- Matched controls
- 2900
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M35.0
ICD-10 Finland
Sicca syndrome [Sjögren]
81.0
229.0
128
28
G73.7*M35.0
ICD-10 Finland
Myopathy in sicca syndrome [Sjögren]
+∞
132.8
117
*
P01BA02
ATC
hydroxychloroquine; oral
17.7
132.5
141
147
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
13.3
108.7
143
198
L04AX01
ATC
azathioprine; systemic
19.0
79.4
68
46
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
9.4
54.0
75
104
L04AA06
ATC
mycophenolic acid; systemic
21.5
46.5
36
19
G73.7
ICD-10 Finland
Myopathy in other diseases classified elsewhere
+∞
46.1
43
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
7.8
45.0
73
120
L04AX03
ATC
methotrexate; systemic
6.8
43.9
84
164
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
73.3
43.8
49
8
H02AB07
ATC
prednisone; oral
5.5
38.6
97
242
M05BA04
ATC
alendronic acid; oral
6.2
35.8
73
150
L01BA01
ATC
methotrexate; systemic
11.9
33.8
36
34
G73.7*M32.1
ICD-10 Finland
Myopathy in systemic lupus erythematosus
+∞
32.9
31
*
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
6.5
31.5
58
107
M32.1
ICD-10 Finland
Systemic lupus erythematosus with organ or system involvement
348.5
31.5
31
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
8.1
30.1
44
63
M35.9
ICD-10 Finland
Systemic involvement of connective tissue, unspecified
30.0
27.9
37
14
H02AB06
ATC
prednisolone; systemic
4.0
27.2
200
1040
G73.0*E05.9
ICD-10 Finland
Myasthenic syndromes in thyrotoxicosis [hyperthyroidism]
+∞
25.4
24
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.5
24.8
169
821
M79.0
ICD-10 Finland
Rheumatism, unspecified
8.4
24.7
34
45
H02AB04
ATC
methylprednisolone; systemic
4.1
24.7
85
264
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.6
24.4
188
983
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.5
22.2
64
173
M32.8
ICD-10 Finland
Other forms of systemic lupus erythematosus
237.1
21.9
22
*
G73.1*C80.99
ICD-10 Finland
Eaton-Lambert syndrome
+∞
21.1
20
*
G73.0*E11.4
ICD-10 Finland
Non-insulin-dependent diabetes mellitus - Diabetic amyotrophy
+∞
20.0
19
*
M32.0
ICD-10 Finland
Drug-induced systemic lupus erythematosus
214.0
19.8
20
*
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
3.1
19.5
184
1035
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.1
19.1
130
608
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.2
18.8
58
164
L88
ICPC
Rheumatoid/seropositive arthritis
6.5
18.7
32
54
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.9
18.3
35
66
H04.10
ICD-10 Finland
Dry eye syndrome
3.6
18.1
71
237
C08CA05
ATC
nifedipine; systemic
5.3
17.9
39
83
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.1
17.8
56
160
G73.7*M34.8
ICD-10 Finland
Myopathy in scleroderma
191.2
17.7
18
*
E05.9
ICD-10 Finland
Thyrotoxicosis, unspecified
7.2
17.3
27
41
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
5.0
17.2
40
90
H19.3*M35.0
ICD-10 Finland
Keratoconjunctivitis sicca
179.9
16.7
17
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
4.1
16.3
50
140
N07AA02
ATC
pyridostigmine; systemic
63.7
15.9
18
*
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
7.7
15.9
23
32
G73.7*M05.3
ICD-10 Finland
Rheumatoid myopathy
+∞
15.8
15
*
G72.9
ICD-10 Finland
Myopathy, unspecified
+∞
15.8
15
*
N06AA09
ATC
amitriptyline; systemic
3.8
15.1
53
163
N06AX21
ATC
duloxetine; oral
3.4
15.1
65
229
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.3
14.8
65
231
M35.1
ICD-10 Finland
Other overlap syndromes
84.5
14.7
16
*
M34.9
ICD-10 Finland
Systemic sclerosis, unspecified
84.5
14.7
16
*
G73.0*E10.4
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic amyotrophy
+∞
14.7
14
*
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
7.1
14.7
23
35
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.1
14.7
74
286
7100A
ICD-9 Finland
Diffuse diseases of connective tissue, Systemic lupus erythematosus
157.6
14.6
15
*
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.7
14.3
50
153
S01XA18
ATC
ciclosporin; ophthalmic
36.0
13.7
17
5
E05.0
ICD-10 Finland
Thyrotoxicosis with diffuse goitre
6.0
13.6
25
45
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
3.9
13.5
43
123
Z01.8
ICD-10 Finland
Other specified special examinations
2.8
13.4
91
412
K11.2
ICD-10 Finland
Sialoadenitis
6.0
13.1
24
43
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.3
12.9
55
191
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
4.4
12.8
34
85
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.8
12.8
43
128
G05.8*M32.1
ICD-10 Finland
Encephalitis in systemic lupus erythematosus
+∞
12.6
12
*
73410
ICD-8 Finland
Diffuse diseases of connective tissue, Systemic lupus erythematosus
135.6
12.5
13
*
C03CA01
ATC
furosemide; systemic
2.5
12.5
110
563
NF1AA
NOMESCO Finland
Hip X-ray examination
3.6
12.1
44
138
NA2AA
NOMESCO Finland
Thoracal spine X-ray examination without contrast
6.2
12.0
21
36
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.9
11.9
27
59
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.6
11.7
93
452
R06.0
ICD-10 Finland
Dyspnoea
2.5
11.7
104
533
G70.0
ICD-10 Finland
Myasthenia gravis
+∞
11.5
11
*
N08.5*M32.1
ICD-10 Finland
Glomerular disorders in systemic lupus erythematosus
124.8
11.5
12
*
N03AX16
ATC
[U] pregabalin
2.5
11.5
96
477
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.0
11.0
54
203
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.3
11.0
45
152
L04AA01
ATC
[U] ciclosporin
16.3
11.0
17
11
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.9
10.7
24
52
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.2
10.7
47
166
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
2.7
10.6
68
296
H03BB01
ATC
carbimazole; oral
4.6
10.5
26
61
M79.7
ICD-10 Finland
Fibromyalgia
4.6
10.5
26
61
M32
ICD-10 Finland
Systemic lupus erythematosus
114.0
10.5
11
*
XCW99
NOMESCO Finland
Other investigative procedure of eye
3.1
10.5
50
185
M34.8
ICD-10 Finland
Other forms of systemic sclerosis
+∞
10.5
10
*
G73.1
ICD-10 Finland
Lambert-Eaton syndrome
+∞
10.5
10
*
108
Kela drug reimbursment
Myasthenia gravis
+∞
10.5
10
*
TPH04
NOMESCO Finland
Cathetrisation of vein
2.5
10.3
82
396
XF400
NOMESCO Finland
ECG with 12 standard connections
2.8
10.2
61
256
XG410
NOMESCO Finland
Flow-volume spirometry
5.2
9.9
21
43
UGC12
NOMESCO Finland
Flexible bronchoscopy
3.6
9.9
34
102
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
5.2
9.5
20
41
M01AH02
ATC
rofecoxib; oral
2.7
9.4
57
240
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.7
9.3
58
247
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.9
9.2
28
77
M05BA07
ATC
risedronic acid; oral
4.8
9.2
21
46
R13
ICD-10 Finland
Dysphagia
3.3
9.2
36
118
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
4.5
9.1
23
55
H53.1
ICD-10 Finland
Subjective visual disturbances
3.5
9.1
33
103
104
Kela drug reimbursment
Thyroid insufficiency
3.3
9.1
36
119
SBB10
NOMESCO Finland
Dental impressions
3.6
9.0
31
93
M35.3
ICD-10 Finland
Polymyalgia rheumatica
4.3
9.0
24
60
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
7.0
8.8
21
32
NXL00
NOMESCO Finland
Biopsy of muscle
51.6
8.7
10
*
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.5
8.5
61
278
GD1AD
NOMESCO Finland
Thorax CT examination
3.9
8.5
26
72
M34.0
ICD-10 Finland
Progressive systemic sclerosis
92.6
8.5
9
*
M33.2
ICD-10 Finland
Polymyositis
92.6
8.5
9
*
WZC10
NOMESCO Finland
Written specialist consultation based on a referral from a dentist or a physician
4.1
8.4
24
63
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.9
8.4
25
68
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.7
8.4
48
196
H03AA01
ATC
levothyroxine sodium; systemic
2.2
8.3
92
506
WX892
NOMESCO Finland
Monitored bed care
3.5
8.3
30
93
Z50.1
ICD-10 Finland
Other physical therapy
3.7
8.2
27
79
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
2.9
8.1
40
150
M01AH01
ATC
celecoxib; oral
2.3
8.1
70
347
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
3.4
8.1
31
100
J01MA12
ATC
levofloxacin; systemic
2.4
8.1
67
326
WZC00
NOMESCO Finland
Treatment plan or consultation
2.1
8.0
116
707
R4120
NOMESCO Finland
Occupational therapy
3.3
8.0
31
101
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
3.1
7.9
34
118
SHA03
NOMESCO Finland
Stomatognathic treatment, demanding
4.4
7.9
20
48
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.9
7.9
39
147
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
6.2
7.8
20
34
R50.9
ICD-10 Finland
Fever, unspecified
2.5
7.8
53
235
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
4.6
7.8
19
44
N03AX12
ATC
[U] gabapentin; oral
2.3
7.8
66
324
EP1AE
NOMESCO Finland
Neck ultrasound examination
3.4
7.8
29
92
X58
ICD-10 Finland
Exposure to other specified factors
2.5
7.8
52
229
ELA30
NOMESCO Finland
Biopsy of salivary gland
46.2
7.8
9
*
M03BA52
ATC
carisoprodol, combinations excl. psycholeptics; oral
4.0
7.7
22
58
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.1
7.7
34
120
E0000UV, ,
ATC
2.0
7.6
139
916
S01KA02
ATC
hypromellose; ophthalmic
6.8
7.5
18
28
Z03.5
ICD-10 Finland
Observation for other suspected cardiovascular diseases
2.9
7.5
36
133
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
2.7
7.5
42
169
UJF32
NOMESCO Finland
Coloscopy
2.1
7.4
90
510
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
8.7
7.4
15
18
L04AA13
ATC
[U] leflunomide
6.5
7.4
18
29
N02AX02
ATC
tramadol; systemic, rectal
2.0
7.3
141
942
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.5
7.3
53
242
M01AE03
ATC
ketoprofen; systemic, rectal
2.0
7.3
126
812
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
6.9
7.2
17
26
M34.1
ICD-10 Finland
CR(E)ST syndrome
20.6
7.2
10
5
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
12.5
7.1
12
10
SBB00
NOMESCO Finland
Clinical photography of mouth and teeth
4.4
7.1
18
43
SBA10
NOMESCO Finland
Measurement of salivary flow rate
10.4
7.1
13
13
M01AX17
ATC
nimesulide; oral
2.1
7.1
88
503
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.3
7.1
27
87
J01FF01
ATC
clindamycin; systemic
2.1
7.0
92
535
X59
ICD-10 Finland
Exposure to unspecified factor
2.3
7.0
63
316
K44.9
ICD-10 Finland
Diaphragmatic hernia without obstruction or gangrene
2.8
7.0
36
138
A01AC01
ATC
triamcinolone; local oral
7.8
7.0
15
20
XCK00
NOMESCO Finland
Perimetry
3.2
7.0
28
93
J02AC01
ATC
fluconazole; systemic
1.9
7.0
141
954
N99
ICPC
Neurological disease other
14.2
6.9
11
8
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
3.1
6.9
29
99
R4110
NOMESCO Finland
Physiotherapy
2.0
6.9
98
587
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
6.9
91
531
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
6.4
6.9
17
28
A02BC02
ATC
pantoprazole; systemic
2.1
6.9
212
1650
K11.71
ICD-10 Finland
Xerostomy (dry mouth)
9.7
6.9
13
14
P01BA01
ATC
chloroquine; systemic
17.2
6.8
10
6
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
17.2
6.8
10
6
M25.5
ICD-10 Finland
Pain in joint
2.0
6.8
112
706
H06.2*E05.9
ICD-10 Finland
Dysthyroid exophthalmos
41.0
6.8
8
*
SHA02
NOMESCO Finland
Stomatognathic treatment, basic
3.0
6.8
30
106
A02BC05
ATC
esomeprazole; systemic
1.9
6.8
137
925
A02BC03
ATC
lansoprazole; oral
2.0
6.7
103
632
L04AD01
ATC
ciclosporin; systemic
8.1
6.7
14
18
J01DB01
ATC
cefalexin; oral
2.4
6.7
249
2072
UJF30
NOMESCO Finland
Ileoscopy through colon
2.5
6.6
43
186
H26.3
ICD-10 Finland
Drug-induced cataract
12.6
6.6
11
9
S97
ICPC
Chronic ulcer skin
3.1
6.6
28
96
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
7.1
6.6
15
22
C08CA02
ATC
felodipine; oral
2.9
6.6
33
125
286
Kela drug reimbursment
Ciclosporin eye drop
71.4
6.5
7
*
TEA00
NOMESCO Finland
Biopsy of lip
14.7
6.4
10
7
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
2.6
6.4
38
157
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
2.7
6.4
36
145
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
2.9
6.3
30
110
M13.9
ICD-10 Finland
Arthritis, unspecified
2.9
6.3
30
110
N17.9
ICD-10 Finland
Acute renal failure, unspecified
5.3
6.3
18
36
L28
ICPC
Limited function/disability (L)
2.2
6.3
64
337
N16.4*M32.1
ICD-10 Finland
Renal tubulo-interstitial disorders in systemic lupus erythematosus
+∞
6.3
6
*
G73.0
ICD-10 Finland
Myasthenic syndromes in endocrine diseases
+∞
6.3
6
*
7102A
ICD-9 Finland
Diffuse diseases of connective tissue, Sicca syndrome[SYNDROMA SICCUM PRIMARIUM]
+∞
6.3
6
*
G70.8
ICD-10 Finland
Other specified myoneural disorders
+∞
6.3
6
*
M60.9
ICD-10 Finland
Myositis, unspecified
27.3
6.3
8
*
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
2.3
6.3
53
259
NH1BA
NOMESCO Finland
Ankle extensive X-ray examination
6.5
6.2
15
24
Z3226
NOMESCO Finland
Physiotherapist
2.1
6.2
68
369
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
3.5
6.1
21
63
N28
ICPC
Limited function/disability (N)
8.9
6.1
12
14
TQW40
NOMESCO Finland
Remowal of suture of skin
2.9
6.1
29
107
UKC02
NOMESCO Finland
Cystoscopy
2.3
6.0
48
228
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
75
70
14.10
72.73
1.7
1.3
6.25
1.78
u/ml
—
32
10
79
80
13.20
72.70
4.9
1.8
—
—
—
0
0
75
71
13.90
72.06
1.7
1.3
2.61
1.99
u/ml
0.69
35
13
66
56
14.96
67.63
1.7
1.3
18.47
11.89
u/ml
—
14
7
60
58
12.78
56.30
1.6
1.3
—
—
—
0
0
86
179
6.41
42.01
4.2
2.6
11.67
10.02
g/l
1.70
74
168
49
56
10.33
40.49
1.7
1.3
63.23
35.90
u/ml
—
14
9
32
24
14.86
34.50
1.4
1.2
70.11
94.40
u/ml
—
9
5
212
1135
4.23
27.92
12.9
5.4
2.73
2.74
%
0.02
207
1053
215
1169
4.24
27.52
13.2
5.6
26.11
28.51
%
2.85
209
1090
212
1159
4.08
26.49
12.4
5.3
59.34
56.97
%
2.23
206
1081
229
1424
3.89
21.28
15.9
9.0
4.04
3.96
e9/l
0.22
213
1247
148
721
3.15
20.58
4.4
2.0
305.74
143.06
u/l
0.52
142
683
60
170
4.19
19.40
11.7
6.3
11.00
9.06
mmol/l
1.09
55
158
51
129
4.58
19.09
8.6
3.2
1.64
1.94
mmol/l
0.20
42
99
185
1057
3.07
18.82
3.3
2.3
81.42
78.31
nmol/l
0.64
172
940
31
23
14.94
18.73
1.4
1.2
2.29
—
u/ml
—
7
0
61
185
3.91
17.88
1.9
2.8
64.64
67.21
g/l
1.42
53
170
120
575
2.85
16.36
3.2
2.1
3.52
3.13
mg/l
0.79
105
491
183
1095
2.82
16.11
10.1
5.3
1.22
1.22
mmol/l
0.55
174
990
86
359
2.98
14.93
2.4
1.8
—
—
—
0
0
190
1196
2.71
14.52
12.2
6.2
1.22
1.22
mmol/l
0.07
163
1018
72
276
3.14
14.47
11.8
5.0
1.04
1.04
mmol/l
0.00
66
248
65
235
3.28
14.40
2.7
4.6
257.05
240.90
u/l
0.63
59
223
149
841
2.59
14.17
6.4
3.0
—
—
—
0
0
84
357
2.90
14.02
3.7
2.8
0.79
0.81
mmol/l
0.54
74
337
133
719
2.57
13.74
5.2
3.1
25.70
142.36
e6/l
0.69
108
544
149
850
2.55
13.73
3.6
3.3
2.35
2.36
mmol/l
0.36
134
751
35
85
4.55
13.65
2.5
1.5
—
—
—
0
0
26
27
10.46
13.53
4.9
1.3
26.43
—
iu/ml
—
7
0
37
95
4.32
13.45
2.2
2.3
1.75
1.67
g/l
0.11
29
81
23
39
6.32
13.27
3.4
3.4
56.78
60.38
%
0.46
23
39
23
39
6.32
13.27
3.3
3.0
3.79
4.93
e9/l
0.90
23
39
21
34
6.58
12.65
1.3
1.1
2.80
1.22
u/ml
—
10
9
22
38
6.18
12.46
1.3
1.1
3.50
4.44
u/ml
0.20
12
16
35
92
4.19
12.32
2.9
1.6
—
—
—
0
0
101
506
2.53
11.94
4.7
2.5
4.06
6.61
e6/l
0.76
94
448
23
44
5.59
11.74
1.5
1.3
—
—
—
0
0
249
1899
3.20
11.56
15.2
7.0
75.19
77.62
u/l
0.50
244
1766
27
61
4.78
11.46
1.1
1.9
—
—
—
0
0
242
1827
2.96
11.25
11.7
4.1
17.25
11.89
mm/h
6.02
234
1676
29
71
4.43
11.16
3.4
2.6
—
—
—
0
0
18
13
14.67
11.12
1.1
1.1
—
—
—
0
0
164
1045
2.31
10.99
7.6
4.0
34.43
36.00
g/l
2.70
149
979
23
47
5.23
10.93
2.1
1.7
125.71
130.66
g/l
0.34
14
32
78
359
2.60
10.88
3.8
2.3
11.01
13.72
umol/l
2.79
72
333
118
659
2.33
10.75
5.3
2.9
0.27
0.47
e6/l
0.94
95
483
37
113
3.61
10.54
2.0
2.2
44.53
40.47
u/l
0.47
32
101
155
977
2.26
10.51
2.3
2.0
103.56
97.61
pmol/l
0.72
84
491
42
140
3.34
10.46
3.9
3.4
4.04
4.57
pmol/l
2.27
37
119
168
1101
2.25
10.27
18.6
11.7
1.20
1.21
inr
0.10
47
322
118
673
2.27
10.10
4.8
3.1
2550.88
1109.08
ng/l
1.23
101
562
163
1070
2.20
9.74
4.0
2.7
145.09
98.28
ug/l
1.65
147
988
68
309
2.57
9.64
4.2
2.3
20.94
23.02
%
0.60
59
263
19
22
9.16
9.45
1.7
1.2
—
—
—
0
0
142
893
2.16
9.35
6.0
3.6
41.20
36.49
ng/l
0.16
108
602
70
327
2.50
9.34
4.0
2.2
2.13
2.40
g/l
2.71
64
301
172
1176
2.14
8.98
5.8
3.7
0.00
0.00
estimate
-0.00
38
230
30
89
3.64
8.90
1.7
2.2
2.90
3.06
g/l
0.31
25
81
100
563
2.18
8.58
1.5
1.3
3.68
1.59
u/ml
0.35
19
154
19
41
4.89
8.48
12.4
5.0
1616.67
139.80
iu/ml
—
6
5
18
37
5.12
8.48
1.5
1.2
—
—
—
0
0
18
38
4.98
8.23
1.9
1.6
—
—
—
0
0
22
55
4.25
8.23
2.1
1.5
—
—
—
0
0
172
1200
2.06
8.23
6.0
3.7
0.00
0.00
estimate
-0.00
33
208
21
51
4.36
8.14
1.8
1.6
—
—
—
0
0
12
7
17.81
8.14
1.1
1.0
—
—
—
0
0
47
193
2.71
8.08
6.1
3.5
107.54
81.98
ng/l
0.89
39
170
18
39
4.85
7.99
1.4
1.6
—
—
—
0
0
18
26
7.31
7.90
2.0
2.0
—
—
—
0
0
83
448
2.19
7.82
2.3
1.7
1262.49
1151.04
nmol/l
0.52
69
335
30
97
3.33
7.81
1.7
2.1
—
—
—
0
0
30
97
3.33
7.81
1.7
2.1
3.29
3.70
g/l
0.76
25
89
30
97
3.33
7.81
1.7
2.1
6.98
7.47
g/l
0.76
25
89
169
1187
2.02
7.76
7.6
4.9
0.00
0.00
estimate
-0.00
36
219
84
457
2.18
7.75
1.4
1.3
46.92
32.25
iu/ml
0.71
37
156
16
20
8.40
7.70
1.3
1.0
—
—
—
0
0
121
760
2.02
7.58
3.3
2.3
54.42
62.32
u/l
0.63
109
698
49
215
2.54
7.36
1.8
2.3
0.21
0.22
g/l
0.51
44
201
16
22
7.63
7.29
1.3
1.2
—
—
—
0
0
16
22
7.63
7.29
1.3
1.2
—
—
—
0
0
24
70
3.65
7.29
1.8
4.5
31.86
27.71
mg/l
0.38
17
57
24
70
3.65
7.29
1.8
4.5
44.89
155.73
mg/l
0.65
18
57
16
23
7.30
7.10
1.3
1.2
—
—
—
0
0
16
23
7.30
7.10
1.3
1.2
—
—
—
0
0
16
23
7.30
7.10
1.3
1.2
—
—
—
0
0
97
575
2.03
7.05
1.6
1.6
21.23
22.11
nmol/l
0.21
85
480
36
140
2.79
6.84
1.4
1.3
289.63
337.84
u/ml
0.08
28
124
42
177
2.61
6.84
1.8
1.4
—
—
—
0
0
21
59
3.76
6.72
1.9
1.5
—
—
—
0
0
19
50
4.00
6.65
2.5
1.5
5809.92
20168.56
e6/l
0.61
13
34
18
34
5.57
6.58
1.2
1.2
—
—
—
0
0
94
564
1.99
6.53
3.0
2.0
—
—
—
0
0
27
92
3.13
6.46
1.7
2.2
11.20
10.36
g/l
0.25
22
83
18
35
5.41
6.44
1.1
1.3
—
—
—
0
0
16
28
5.98
6.24
1.5
1.6
—
—
—
0
0
183
1383
1.88
6.12
7.5
4.3
6.54
6.59
mmol/l
0.11
171
1287
11
11
10.34
6.08
1.0
1.2
119.36
61.10
u/l
1.92
11
11
11
11
10.34
6.08
1.0
1.2
46.55
17.61
u/l
0.97
11
11
25
85
3.12
6.01
1.9
2.6
0.15
0.88
g/l
1.45
19
76
32
126
2.73
5.94
1.8
1.7
—
—
—
0
0
24
81
3.14
5.84
1.7
1.4
313.06
315.89
ug/g
0.03
16
44
31
122
2.73
5.76
1.5
1.3
—
—
—
0
0
60
322
2.09
5.58
4.3
4.3
32.24
32.63
%
0.11
46
209
101
649
1.85
5.57
6.2
4.0
0.00
0.00
estimate
-0.00
34
220
80
477
1.94
5.55
2.7
2.7
2.46
2.45
mmol/l
0.24
71
423
172
1300
1.79
5.49
7.3
5.6
9.15
10.55
umol/l
1.99
161
1234
19
58
3.44
5.41
2.7
1.4
—
—
—
0
0
87
539
1.88
5.35
2.2
1.6
1.12
0.98
mg/l
0.31
68
425
13
22
6.13
5.28
2.3
1.9
—
—
—
0
0
95
609
1.83
5.23
4.0
2.7
352.59
6609.77
umol/l
2.69
81
530
23
81
3.00
5.22
1.9
2.3
36.99
38.06
g/l
0.29
18
73
153
1129
1.75
5.20
2.9
2.3
—
—
—
0
0
20
65
3.23
5.17
1.4
1.1
—
—
—
0
0
14
27
5.39
5.15
1.4
1.7
—
—
—
0
0
48
244
2.16
5.12
1.8
1.9
—
—
—
0
0
68
394
1.95
5.09
3.9
2.6
0.57
1.05
e6/l
2.06
43
211
9
9
10.27
5.06
2.0
2.0
—
—
—
0
0
9
9
10.27
5.06
2.0
2.0
—
—
—
0
0
9
9
10.27
5.06
2.0
2.0
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
18
57
3.30
4.85
3.7
2.3
0.21
0.39
u/ml
—
10
28
13
25
5.39
4.83
2.3
1.8
—
—
—
0
0
11
17
6.68
4.82
1.4
1.0
—
—
—
0
0
79
493
1.83
4.68
1.6
1.8
465.03
465.39
pmol/l
0.00
64
409
14
31
4.69
4.62
1.4
1.7
—
—
—
0
0
73
447
1.85
4.59
1.3
1.3
15.80
10.71
u/ml
0.15
17
164
228
1926
1.86
4.51
6.0
4.1
15.18
14.74
pmol/l
1.58
208
1741
10
15
6.86
4.50
2.5
1.7
—
—
—
0
0
10
15
6.86
4.50
2.5
1.7
—
—
—
0
0
47
250
2.05
4.45
2.0
1.9
—
—
—
0
0
19
66
3.01
4.42
1.7
2.3
10.94
11.86
mg/l
0.22
19
60
112
784
1.70
4.42
3.6
2.9
31.08
28.73
u/l
0.61
104
749
15
39
4.00
4.26
2.5
1.6
—
—
—
0
0
15
39
4.00
4.26
2.5
1.6
—
—
—
0
0
18
63
2.98
4.14
2.2
1.5
10.32
5.94
iu/l
—
6
20
11
22
5.15
4.04
2.4
1.8
—
—
—
0
0
11
22
5.15
4.04
2.4
1.8
—
—
—
0
0
11
22
5.15
4.04
2.4
1.8
—
—
—
0
0
39
204
2.05
3.86
2.1
2.4
3.89
6.14
ug/l
0.71
28
181
7
8
8.93
3.79
1.4
1.5
—
—
—
0
0
41
220
2.01
3.79
5.0
3.3
—
—
—
0
0
8
12
6.82
3.69
1.4
1.3
—
—
—
0
0
7
9
7.93
3.58
1.4
1.4
—
—
—
0
0
194
1614
1.61
3.53
4.8
2.9
50.81
45.49
u/l
0.39
180
1510
12
32
3.87
3.43
1.7
1.4
—
—
—
0
0
58
361
1.76
3.40
4.2
2.8
3.50
2.97
e6/l
0.16
34
180
9
18
5.12
3.40
1.8
2.1
—
—
—
0
0
9
18
5.12
3.40
1.1
1.1
—
—
—
0
0
7
10
7.14
3.38
2.9
2.2
—
—
—
0
0
7
10
7.14
3.38
1.4
1.6
—
—
—
0
0
10
23
4.46
3.34
1.7
1.3
—
—
—
0
0
8
16
5.11
3.07
1.1
1.3
—
—
—
0
0
8
16
5.11
3.07
1.4
1.0
—
—
—
0
0
13
45
2.98
3.06
1.9
1.5
—
—
—
0
0
44
260
1.82
3.06
7.7
6.8
1.11
1.34
mmol/l
0.13
37
214
5
5
10.14
2.99
1.8
1.4
—
—
—
0
0
49
302
1.75
2.96
8.4
6.6
—
—
—
0
0
8
17
4.81
2.94
1.3
1.1
—
—
—
0
0
7
13
5.49
2.88
1.1
1.1
—
—
—
0
0
35
196
1.89
2.87
7.7
3.8
5.73
5.88
kpa
0.50
35
191
34
189
1.91
2.85
7.1
3.4
1.22
1.23
mmol/l
0.50
29
169
5
6
8.45
2.76
1.0
1.2
106.40
103.17
%
—
5
6
67
458
1.60
2.74
5.4
3.6
1074.32
177.82
ng/l
0.58
53
346
97
722
1.52
2.73
6.2
3.7
16.92
6.42
mg/mmol
1.52
63
431
264
2436
1.93
2.69
35.0
12.9
23.85
21.87
mg/l
0.39
241
1891
5
7
7.24
2.56
1.0
1.0
1752.00
1636.14
miu/ml
—
5
7
9
27
3.41
2.41
1.3
1.0
—
—
—
0
0
115
905
1.45
2.39
6.4
3.8
—
—
—
0
0
8
22
3.71
2.38
1.9
1.2
—
—
—
0
0
15
65
2.38
2.35
1.5
2.1
15.46
4388.76
u/l
—
5
21
14
59
2.44
2.33
1.4
1.2
—
—
—
0
0
250
2295
1.65
2.27
7.2
4.9
1.78
2.41
mu/l
0.63
232
2090
9
29
3.17
2.24
1.3
1.0
—
—
—
0
0
61
427
1.54
2.24
1.7
1.5
—
—
—
0
0
5
9
5.63
2.22
1.2
1.1
—
—
—
0
0
6
14
4.35
2.16
1.8
1.1
—
—
—
0
0
12
49
2.51
2.13
1.3
1.7
—
—
—
0
0
10
37
2.76
2.09
1.2
1.1
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
5
10
5.07
2.08
1.4
2.1
104.80
117.40
%
—
5
10
40
258
1.64
2.06
1.5
1.9
1.48
1.49
%
0.00
33
230
12
50
2.46
2.05
1.5
1.3
—
—
—
0
0
10
38
2.69
2.02
1.3
1.3
—
—
—
0
0
10
38
2.69
2.02
1.3
1.3
—
—
—
0
0
10
38
2.69
2.02
1.3
1.3
—
—
—
0
0
10
38
2.69
2.02
1.3
1.3
—
—
—
0
0
10
38
2.69
2.02
1.3
1.3
—
—
—
0
0
10
38
2.69
2.02
1.3
1.3
—
—
—
0
0
17
85
2.06
1.94
1.9
1.7
—
—
—
0
0
6
16
3.81
1.94
1.8
1.2
2.45
1.86
mmol/l
—
6
16
30
184
1.70
1.87
2.2
2.4
52.79
68.90
ml/min/173m2
1.62
17
73
6
17
3.58
1.84
6.7
1.6
14.73
17.16
ug/l
—
6
17
5
12
4.22
1.83
1.2
1.2
95.80
94.42
%
—
5
12
13
60
2.22
1.80
1.2
1.3
—
—
—
0
0
8
29
2.81
1.80
1.1
1.2
—
—
—
0
0
8
29
2.81
1.80
1.1
1.1
—
—
—
0
0
7
24
2.96
1.73
1.0
1.0
—
—
—
0
0
5
13
3.89
1.72
1.0
1.0
—
—
—
0
0
23
135
1.76
1.68
8.0
8.4
94.12
94.30
%
0.05
23
135
40
273
1.54
1.65
8.8
6.3
103.90
103.93
mmol/l
0.01
40
273
5
14
3.61
1.62
1.4
2.9
1328.80
631.71
u/ml
—
5
14
69
530
1.40
1.57
6.8
4.1
1.02
1.02
kg/l
0.03
16
64
168
1477
1.33
1.57
3.0
3.0
—
—
—
0
0
26
163
1.65
1.52
4.9
2.6
4.44
4.44
kpa
0.01
26
158
12
227
0.51
1.51
1.6
1.7
—
—
—
0
0
37
258
1.50
1.40
2.5
2.2
3.74
7.61
umol/l
3.51
31
224
35
242
1.51
1.38
3.5
2.2
34.87
29.28
u/l
0.67
30
209
29
194
1.55
1.33
2.2
2.9
38.48
46.09
u/ml
0.14
29
188
6
24
2.53
1.31
2.2
1.6
—
—
—
0
0
6
24
2.53
1.31
2.2
1.6
—
—
—
0
0
6
25
2.43
1.25
1.3
2.1
—
—
—
0
0
9
45
2.03
1.24
1.6
1.5
—
—
—
0
0
9
45
2.03
1.24
1.6
1.5
—
—
—
0
0
8
37
2.19
1.22
3.4
1.3
—
—
nmol/l
—
0
0
5
20
2.53
1.15
1.6
1.2
—
—
—
0
0
7
30
2.37
1.13
1.1
1.2
—
—
—
0
0
27
186
1.50
1.11
1.2
1.2
197.44
172.91
iu/ml
—
9
83
11
60
1.87
1.04
1.4
1.3
—
—
—
0
0
60
488
1.29
0.94
1.6
1.4
—
—
—
0
0
6
28
2.17
0.92
1.7
1.2
—
—
—
0
0
6
32
1.89
0.82
3.5
3.6
—
—
—
0
0
243
2325
1.28
0.80
26.6
12.4
76.08
80.51
ml/min/173m2
2.01
222
1893
6
33
1.83
0.79
1.5
1.4
3.35
10.09
u/ml
—
6
33
9
56
1.63
0.73
1.2
1.3
—
—
—
0
0
20
143
1.43
0.72
1.5
1.3
—
—
—
0
0
14
93
1.53
0.71
1.2
1.2
—
—
—
0
0
0
23
0.00
0.58
0.0
2.6
—
13.50
—
0
23
33
268
1.26
0.55
2.7
4.1
3.41
23.14
ug/l
0.69
24
226
9
60
1.52
0.55
1.1
1.1
—
—
—
0
0
13
93
1.42
0.49
1.2
1.2
—
—
—
0
0
245
2378
1.20
0.48
5.4
4.6
6.02
5.91
mmol/l
0.41
224
2180
9
68
1.33
0.38
1.7
1.4
—
264.62
—
0
30
8
115
0.69
0.37
1.9
1.6
—
—
—
0
0
5
71
0.70
0.26
1.6
1.4
—
—
—
0
0
267
2700
0.86
0.23
47.7
19.4
38.45
40.07
%
3.74
257
2538
233
2286
1.10
0.22
7.4
5.6
40.25
39.61
mmol/mol
0.39
213
2124
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
0
10
0.00
0.21
0.0
2.7
—
—
—
0
0
0
14
0.00
0.20
0.0
7.6
—
42.40
—
0
5
23
207
1.12
0.15
1.7
1.7
—
—
—
0
0
7
88
0.79
0.14
1.6
1.6
—
—
—
0
0
250
2473
1.08
0.13
5.6
5.0
2.69
2.80
mmol/l
1.12
228
2280
25
229
1.10
0.13
1.8
1.9
—
—
—
0
0
31
333
0.92
0.12
3.8
4.6
26.05
21.76
%
0.60
14
160
11
96
1.15
0.10
1.3
1.4
—
—
—
0
0
243
2410
1.05
0.08
5.1
4.4
1.47
1.54
mmol/l
1.49
222
2224
234
2320
1.04
0.08
4.7
3.9
1.40
1.27
mmol/l
1.79
210
2123
9
86
1.05
0.07
1.3
1.4
—
—
—
0
0
244
2428
1.03
0.04
5.1
4.5
4.62
4.77
mmol/l
1.49
223
2249
72
707
1.02
0.04
1.6
1.7
1.79
1.37
mmol/l
0.60
61
602
25
252
0.99
0.00
3.5
2.9
0.75
0.69
ug/l
0.12
18
157
13
129
1.01
0.00
1.2
1.0
—
—
—
0
0
10
104
0.96
0.00
5.3
2.3
1.12
1.15
%
—
10
104
0
9
0.00
-0.00
0.0
1.0
—
21.06
—
0
9
0
7
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
10
100
1.00
-0.00
5.3
2.4
0.61
0.68
%
—
10
100
0
6
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint G6_MYOMUSCINOTH and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYOMUSCINOTH | 2.496 [2.04, 3.06] | < 0.001 |
| Birth year | 1.002 [0.99, 1.01] | 0.715 |
During the follow-up period (1.1.1998 — 31.12.2019), 313 out of 874 females with G6_MYOMUSCINOTH died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| G6_MYOMUSCINOTH | 2.303 [1.64, 3.22] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | 0.002 |
During the follow-up period (1.1.1998 — 31.12.2019), 124 out of 312 males with G6_MYOMUSCINOTH died.
Mortality risk
Mortality risk for people of age
years, who have G6_MYOMUSCINOTH.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.284% | 0.376% |
| 5 | 1.534% | 2.586% |
| 10 | 3.878% | 6.089% |
| 15 | 7.889% | 11.542% |
| 20 | 14.235% | 18.932% |
Relationships between endpoints
↥Index endpoint: G6_MYOMUSCINOTH – Disorders of myoneural junction and muscle in diseases classified elsewhere
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data